Literature DB >> 10563222

Acute quadriplegic myopathy unrelated to steroids or paralyzing agents: quantitative EMG studies.

A Höke1, N B Rewcastle, D W Zochodne.   

Abstract

BACKGROUND: Quadriplegic myopathy (QM) and its variants generally are described in critically ill patients who are exposed to steroids and nondepolarizing muscle blocking agents (NDMBAs).
METHODS: A patient with sepsis who was not exposed to steroids or an NDMBA infusion developed QM and was studied using serial quantitative electromyography.
RESULTS: Clinical and electrophysiological studies identified evidence of a severe myopathy and muscle biopsy showed necrosis, calcifications and selective loss of myosin filaments in non-necrotic fibers. Her clinical recovery paralleled rises in motor unit action potential (MUAP) amplitudes studied by serial automatic decomposition electromyography (ADEMG).
CONCLUSIONS: QM can develop with sepsis and without significant exposure to steroids and NDMBAs. ADEMG can be a useful tool in electrophysiological evaluation of critically ill patients with weakness.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10563222     DOI: 10.1017/s0317167100000482

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  4 in total

1.  Origin of ICU acquired paresis determined by direct muscle stimulation.

Authors:  J-P Lefaucheur; T Nordine; P Rodriguez; L Brochard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

Review 2.  Critical illness myopathy and polyneuropathy.

Authors:  Shawn J Bird; Mark M Rich
Journal:  Curr Neurol Neurosci Rep       Date:  2002-11       Impact factor: 5.081

Review 3.  Approach to neuromuscular disorders in the intensive care unit.

Authors:  Kenneth C Gorson
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Mechanisms underlying ICU muscle wasting and effects of passive mechanical loading.

Authors:  Monica Llano-Diez; Guillaume Renaud; Magnus Andersson; Humberto Gonzales Marrero; Nicola Cacciani; Henrik Engquist; Rebeca Corpeño; Konstantin Artemenko; Jonas Bergquist; Lars Larsson
Journal:  Crit Care       Date:  2012-10-26       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.